Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

  • MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30%
     
  • Overall survival benefit for Kisqali plus fulvestrant was consistent regardless of line of therapy or response to prior endocrine treatment
     
  • Kisqali is the only CDK4/6 inhibitor to demonstrate consistently superior overall survival in two Phase III trials, proven with multiple combination partners and in two …
/by